This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
Wall Street Brushes Off Trade War Fears: Top 5 Gainers
by Tirthankar Chakraborty
The Dow climbed more than 700 points after investors downplayed fears over tariffs announced by both China and the United States.
Is Addus HomeCare (ADUS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Addus HomeCare (ADUS) could be an interesting play for investors as it is seeing solid earnings estimate revision in addition to having a robust industry rank.
Addus HomeCare (ADUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Addus HomeCare Corporation (ADUS).
New Strong Sell Stocks for December 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for November 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
On Jun 23, we issued an updated research report on Denver, CO-based DaVita HealthCare Partners Inc. (DVA).
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment
by Zacks Equity Research
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment
Avoid Market Volatility with 5 Low-Beta Stocks
by Zacks Equity Research
In this article, we present a strategy which proves that low risky securities can also reap rewards if some specific parameters are considered.
Zacks.com featured highlights: Summer Infant, TerraVia Holdings, Addus HomeCare,Schnitzer Steel Industries and Research Frontiers
by Zacks Equity Research
Zacks.com featured highlights: Summer Infant, TerraVia Holdings, Addus HomeCare,Schnitzer Steel Industries and Research Frontiers
New Strong Buy Stocks for May 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Use Rising P/E Tactic to Find Out 5 Winning Stocks
by Zacks Equity Research
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.
Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
HealthSouth Corp (HLS) Looks Good: Stock Moves 8% Higher
by Zacks Equity Research
HealthSouth Corporation (HLS) shares rose almost 8% in the last trading session.
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion
by Zacks Equity Research
Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
VIVUS to Regain Commercial Rights for Stendra from Sanofi
by Zacks Equity Research
VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA
by Zacks Equity Research
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
Allergan's Restasis Now Available in Multidose Bottle in U.S.
by Zacks Equity Research
Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.
Alexion (ALXN) Files for Soliris' Label Expansion in Japan
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).
Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.
Keryx's Auryxia Added to Largest Medicare Part D Plan
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down
by Zacks Equity Research
Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.
Jazz Sleep Disorder Drug Positive in Phase III Studies
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.